Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval by the European Commission to include an indication for Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease.

Bron: Pharmafile | lees verder..